[Form 4] Celldex Therapeutics, Inc Insider Trading Activity
Celldex Therapeutics insider sale disclosure: Freddy A. Jimenez, SVP & General Counsel and officer of Celldex Therapeutics, reported two open-market dispositions of common stock on 08/13/2025. He sold 341 shares at $23.9515 and 430 shares at $25.415. After these transactions he beneficially owned 34,962 shares. The filing notes 269 of the reported shares were acquired under the company鈥檚 2004 Employee Stock Purchase Plan. The Form 4 was signed by an attorney-in-fact on 08/15/2025.
Dichiarazione di vendita da parte di un insider di Celldex Therapeutics: Freddy A. Jimenez, SVP & General Counsel e dirigente di Celldex Therapeutics, ha effettuato due cessioni in mercato aperto di azioni ordinarie il 13/08/2025. Ha venduto 341 azioni a $23,9515 e 430 azioni a $25,415. Dopo queste operazioni risultava beneficiario di 34.962 azioni. Il documento indica che 269 delle azioni segnalate erano state acquistate nell'ambito del Piano di Acquisto Azionario per i Dipendenti del 2004 della societ脿. Il Modulo 4 猫 stato firmato da un procuratore il 15/08/2025.
Divulgaci贸n de venta por parte de un insider de Celldex Therapeutics: Freddy A. Jimenez, SVP & General Counsel y ejecutivo de Celldex Therapeutics, comunic贸 dos disposiciones en mercado abierto de acciones ordinarias el 13/08/2025. Vendi贸 341 acciones a $23.9515 y 430 acciones a $25.415. Tras estas transacciones, era beneficiario de 34.962 acciones. La presentaci贸n indica que 269 de las acciones reportadas fueron adquiridas bajo el Plan de Compra de Acciones para Empleados 2004 de la empresa. El Formulario 4 fue firmado por un apoderado el 15/08/2025.
Celldex Therapeutics 雮措秬鞛� 毵る弰 瓿奠嫓: Freddy A. Jimenez(靾橃劃 攵�靷灔 瓴� 氩曤雼措嫻 鞛勳洂)電� 2025雲� 8鞗� 13鞚� 氤错喌欤� 鞛ル偞 毵る弰毳� 霊� 瓯� 氤搓碃頄堨姷雼堧嫟. 341欤茧ゼ 欤茧嫻 $23.9515鞐�, 430欤茧ゼ 欤茧嫻 $25.415鞐� 毵る弰頄堨姷雼堧嫟. 鞚� 瓯半灅 鞚错泟 攴戈皜 鞁れ鞝侅溂搿� 氤挫湢頃� 欤检嫕 靾橂姅 34,962欤检榾鞀惦媹雼�. 氤搓碃靹滌棎電� 鞁犼碃霅� 欤检嫕 欷� 269欤缄皜 須岇偓鞚� 2004雲� 歆侅洂 欤检嫕 毵れ垬 瓿勴殟鞐� 霐半澕 旆摑霅� 瓴冹澊霛缄碃 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. Form 4電� 2025雲� 8鞗� 15鞚检棎 雽�毽澑鞚� 靹滊獏頄堨姷雼堧嫟.
Divulgation d'une vente par un initi茅 de Celldex Therapeutics : Freddy A. Jimenez, SVP & General Counsel et dirigeant de Celldex Therapeutics, a d茅clar茅 deux cessions en march茅 libre d'actions ordinaires le 13/08/2025. Il a vendu 341 actions 脿 23,9515 $ et 430 actions 脿 25,415 $. Apr猫s ces op茅rations, il d茅tenait effectivement 34 962 actions. Le dossier pr茅cise que 269 des actions d茅clar茅es ont 茅t茅 acquises dans le cadre du Plan d'achat d'actions pour employ茅s de 2004 de la soci茅t茅. Le Formulaire 4 a 茅t茅 sign茅 par un mandataire le 15/08/2025.
Offenlegung eines Insider-Verkaufs bei Celldex Therapeutics: Freddy A. Jimenez, SVP & General Counsel und leitender Angestellter von Celldex Therapeutics, meldete am 13.08.2025 zwei Verk盲ufe von Stammaktien am offenen Markt. Er ver盲u脽erte 341 Aktien zu $23,9515 und 430 Aktien zu $25,415. Nach diesen Transaktionen besa脽 er wirtschaftlich 34.962 Aktien. In der Einreichung wird angegeben, dass 269 der gemeldeten Aktien im Rahmen des Employee Stock Purchase Plan von 2004 des Unternehmens erworben wurden. Das Formular 4 wurde am 15.08.2025 von einem Bevollm盲chtigten unterschrieben.
- None.
- Insider dispositions reported: The officer sold a total of 771 shares in open-market transactions on 08/13/2025.
Insights
TL;DR: Officer reported routine, small open-market sales; disclosure complies with Section 16 reporting requirements.
The transactions are straightforward dispositions executed on 08/13/2025 and properly reported on Form 4. The reporting person remains an officer and retains approximately 34,962 shares after the sales. The filing also discloses a small ESPP acquisition of 269 shares, which is routine compensation-related activity. There is no indication of accelerated or atypical derivative activity, amendments, or clustering of insider trades in this filing.
TL;DR: Two small insider sales were reported; amounts and post-sale holdings are modest relative to typical market cap considerations.
The Form 4 shows two separate sales at prices of $23.9515 and $25.415 for 341 and 430 shares respectively. Post-transaction beneficial ownership is disclosed as 34,962 shares. The filing provides clear prices and share counts and notes the ESPP acquisition. From a disclosure and market-transparency standpoint, the report is complete and timely based on the information provided.
Dichiarazione di vendita da parte di un insider di Celldex Therapeutics: Freddy A. Jimenez, SVP & General Counsel e dirigente di Celldex Therapeutics, ha effettuato due cessioni in mercato aperto di azioni ordinarie il 13/08/2025. Ha venduto 341 azioni a $23,9515 e 430 azioni a $25,415. Dopo queste operazioni risultava beneficiario di 34.962 azioni. Il documento indica che 269 delle azioni segnalate erano state acquistate nell'ambito del Piano di Acquisto Azionario per i Dipendenti del 2004 della societ脿. Il Modulo 4 猫 stato firmato da un procuratore il 15/08/2025.
Divulgaci贸n de venta por parte de un insider de Celldex Therapeutics: Freddy A. Jimenez, SVP & General Counsel y ejecutivo de Celldex Therapeutics, comunic贸 dos disposiciones en mercado abierto de acciones ordinarias el 13/08/2025. Vendi贸 341 acciones a $23.9515 y 430 acciones a $25.415. Tras estas transacciones, era beneficiario de 34.962 acciones. La presentaci贸n indica que 269 de las acciones reportadas fueron adquiridas bajo el Plan de Compra de Acciones para Empleados 2004 de la empresa. El Formulario 4 fue firmado por un apoderado el 15/08/2025.
Celldex Therapeutics 雮措秬鞛� 毵る弰 瓿奠嫓: Freddy A. Jimenez(靾橃劃 攵�靷灔 瓴� 氩曤雼措嫻 鞛勳洂)電� 2025雲� 8鞗� 13鞚� 氤错喌欤� 鞛ル偞 毵る弰毳� 霊� 瓯� 氤搓碃頄堨姷雼堧嫟. 341欤茧ゼ 欤茧嫻 $23.9515鞐�, 430欤茧ゼ 欤茧嫻 $25.415鞐� 毵る弰頄堨姷雼堧嫟. 鞚� 瓯半灅 鞚错泟 攴戈皜 鞁れ鞝侅溂搿� 氤挫湢頃� 欤检嫕 靾橂姅 34,962欤检榾鞀惦媹雼�. 氤搓碃靹滌棎電� 鞁犼碃霅� 欤检嫕 欷� 269欤缄皜 須岇偓鞚� 2004雲� 歆侅洂 欤检嫕 毵れ垬 瓿勴殟鞐� 霐半澕 旆摑霅� 瓴冹澊霛缄碃 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. Form 4電� 2025雲� 8鞗� 15鞚检棎 雽�毽澑鞚� 靹滊獏頄堨姷雼堧嫟.
Divulgation d'une vente par un initi茅 de Celldex Therapeutics : Freddy A. Jimenez, SVP & General Counsel et dirigeant de Celldex Therapeutics, a d茅clar茅 deux cessions en march茅 libre d'actions ordinaires le 13/08/2025. Il a vendu 341 actions 脿 23,9515 $ et 430 actions 脿 25,415 $. Apr猫s ces op茅rations, il d茅tenait effectivement 34 962 actions. Le dossier pr茅cise que 269 des actions d茅clar茅es ont 茅t茅 acquises dans le cadre du Plan d'achat d'actions pour employ茅s de 2004 de la soci茅t茅. Le Formulaire 4 a 茅t茅 sign茅 par un mandataire le 15/08/2025.
Offenlegung eines Insider-Verkaufs bei Celldex Therapeutics: Freddy A. Jimenez, SVP & General Counsel und leitender Angestellter von Celldex Therapeutics, meldete am 13.08.2025 zwei Verk盲ufe von Stammaktien am offenen Markt. Er ver盲u脽erte 341 Aktien zu $23,9515 und 430 Aktien zu $25,415. Nach diesen Transaktionen besa脽 er wirtschaftlich 34.962 Aktien. In der Einreichung wird angegeben, dass 269 der gemeldeten Aktien im Rahmen des Employee Stock Purchase Plan von 2004 des Unternehmens erworben wurden. Das Formular 4 wurde am 15.08.2025 von einem Bevollm盲chtigten unterschrieben.
FAQ
What trades did Freddy A. Jimenez report for CLDX on 08/13/2025?
How many CLDX shares does Freddy A. Jimenez own after the reported transactions?
Were any shares acquired under an employee plan noted in the Form 4?
Who signed the Form 4 filing for Freddy A. Jimenez?
What is the reporting person鈥檚 role at Celldex (CLDX)?
